The Scientific Session of the Myasthenia Gravis Foundation of America, Inc. (MGFA) is an annual meeting that provides medical professionals the opportunity to learn about, and share work on current, pre-publication research related to disorders of the neuromuscular junction. The session is intended for neurologists and other medical professionals, but is open to the public.

### Topics
All abstracts must emphasize clinical or basic research related to myasthenia gravis or other disorders of the neuromuscular junction.

### Instructions
Authors need not be members of Myasthenia Gravis Foundation of America, Inc. (MGFA) nor sponsored by a member. All are welcome to submit abstracts. Acceptance is entirely upon quality. Poster presentations are encouraged. Presentations are generally works in progress.

### Structure and Length of Abstract
Abstracts should be in a structured format as outlined by the National Library of Medicine, including sections labeled: **Introduction**, **Objective/Methods**, **Results**, and **Summary/Conclusion**.

Abstracts should not exceed 250 words in length excluding subject headers, same requirements as per AANEM. Abstracts must contain all authors name, city, state, country.

### Deadline
Deadline for receipt of abstracts is **June 11, 2020**.

### Abbreviations
Please spell out all abbreviated terms at the first use. We will accept abbreviations allowed under the AANEM abstract submission. For more details, please see 2020 AANEM FAQs: [https://www.aanem.org/getmedia/04ab6cc0-cb16-49a8-841f-52fc665d0811/Abstract-FAQs-2020-v1.pdf](https://www.aanem.org/getmedia/04ab6cc0-cb16-49a8-841f-52fc665d0811/Abstract-FAQs-2020-v1.pdf)

### References
When citing references, provide name of first author, title of book or journal name and year published.

### Restrictions
No continuation page, illustrations or tables are to be included. In general, abstracts should report work not previously presented or published, but exceptions for topics of particular interest may be considered. Authors should cite the publication/conference in which the work was previously presented at the opening of the abstract, as applicable. Concurrent submission of

---

**Call For Abstracts**

**MGFA Scientific Session:**
**Wednesday, October 7**
8:00 am – 12:00 Noon

**Held in conjunction with the AANEM Annual Meeting**
**October 7-10**

**Location:** JW Marriott Grande Lakes
4040 Central Florida Parkway
Orlando, FL 32837

---

**Scientific Session 2020**

**mg**

**MYASTHENIA GRAVIS FOUNDATION OF AMERICA**
an abstract to the 2020 AANEM meeting and to the 2020 MGFA scientific session is permitted.

**Disclosure Statement**
This statement (see below) must be completed by first author in order for abstract to be considered. You will be prompted by the AANEM system to provide disclosures.

**Submission of Abstracts**
All abstracts must be submitted through the AANEM portal. Please use the following link and instructions: [www.aanem.org/mgfaabstracts](http://www.aanem.org/mgfaabstracts)

**Accepted Abstracts**

**Notification**
Authors of accepted abstracts will be notified by July 1, 2020.

**Publication**
All accepted abstracts will be published in *Muscle and Nerve*. A summary of presentations will also be provided on the MGFA website (myasthenia.org) and in the MGFA Focus on MG magazine.

**Type of Presentation**
A limited number of abstracts will be chosen for platform presentation. All other presentations will be poster presentations.

**Deadline: June 11, 2020**

Please direct questions to MGFA at:
Telephone: (800) 541-5454
Email: jhughson-andrade@myasthenia.org
ABSTRACT SUBMISSION FOR CONSIDERATION AS A SCIENTIFIC POSTER DISCLOSURE/AFFIRMATION

Disclosure: ALL AUTHORS must agree to the following statements before this abstract can be submitted.

By submitting this abstract for presentation for consideration at the annual Scientific Session of the Myasthenia Gravis Foundation of America, Inc. (MGFA), part of the 65th Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), we affirm that this submission conforms to all abstract policies and procedures listed. We certify that the authors named on this abstract submission are familiar with the presented material, agree with the results as stated, and have specifically consented to be included as speakers. We affirm that the information contained in this abstract fairly and accurately represents original work. We assume full responsibility for securing the necessary clearance and permission for publication and presentation from any contracting supervisory research agency holding presentation material copyrights.

All expenses related to poster design, printing and shipping will be the responsibility of the presenter. Additional details will be provided at the time of abstract acceptance.

The MGFA & AANEM require that all speakers at programs granting CME credit provide a financial disclosure statement. We agree that any and all financial interests in the product or process involved with our presentation will be properly identified. This includes stock ownership, membership on an advisory board or board of directors, corporate sponsored research, or any other substantive relationships. We certify, represent, and warrant that we have the right to publish this abstract as submitted and agree to indemnify the MGFA & AANEM from any claims arising from this material.

The primary author assumes responsibility for the authenticity of the work and all information related to this abstract. No abstracts will be accepted promoting specific companies or pharmaceuticals. All drugs and equipment noted in the abstract must be listed by generic name, if at all possible. It is important that abstracts be clearly written. Those not easily understood are likely to be rejected. For those submitters for whom English is not the native language, we strongly recommend prior to submission that the abstract be edited by a native English speaker, or by a professional editing service. This will greatly enhance the chance of acceptance.

Authors need not be members of the MGFA nor be sponsored by a member. All are welcome to submit abstracts. Acceptance is based entirely upon quality. Poster presentations are encouraged. Presentations are generally works in progress. Neurology residents in training may be eligible for the MGFA John Newsom-Davis Memorial Award which covers supplemental funds for Neurology-in-Training (registrars, residents or fellows) to attend or present at scientific or clinical meetings related to myasthenia gravis. It is strongly encouraged that applicants present a scientific paper at the proposed meeting. Contact Jessica Hughson-Andrade, MPA, Director of Programs, at jhughson-andrade@myasthenia.org for an application.

No additional authors may be added after it is submitted. A limited number of abstracts will be chosen for platform presentation. All other presentations will be poster presentations. For questions, comments or concerns regarding the online abstract system, please contact the AANEM meetings department.

The person entering the information is required to input their contact information, the abstract, and add the information regarding additional authors to be included on the abstract. Before beginning the process, it is best to have the address information for all the others as well as their disclosure information. You can, however, save at the end and come back into the system to add information as needed.

Deadline for submission of abstracts is June 11. Authors of accepted abstracts will be notified by July 1. All accepted abstracts will be published in Muscle and Nerve. A summary of the presentations will also be provided on the MGFA website and in the MGFA’s magazine.